Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Liabilities (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Total Liabilities for 16 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 8.16% year-over-year to $1.0 billion, compared with a TTM value of $1.0 billion through Dec 2025, up 8.16%, and an annual FY2025 reading of $919.2 million, down 3.11% over the prior year.
  • Total Liabilities was $1.0 billion for Q4 2025 at Arrowhead Pharmaceuticals, up from $919.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.0 billion in Q4 2025 and bottomed at $251.3 million in Q1 2022.
  • Average Total Liabilities over 5 years is $543.1 million, with a median of $456.2 million recorded in 2023.
  • The sharpest move saw Total Liabilities skyrocketed 493.98% in 2021, then dropped 19.26% in 2022.
  • Year by year, Total Liabilities stood at $266.0 million in 2021, then surged by 86.15% to $495.1 million in 2022, then decreased by 8.59% to $452.6 million in 2023, then skyrocketed by 111.59% to $957.6 million in 2024, then grew by 8.16% to $1.0 billion in 2025.
  • Business Quant data shows Total Liabilities for ARWR at $1.0 billion in Q4 2025, $919.2 million in Q3 2025, and $860.8 million in Q2 2025.